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ABSTRACT 
Objective 
To compare different strategies predicting hyperkalemia (serum potassium level 
≥5.5mEq/l) in hospitalized patients for whom medications triggering potassium-
increasing drug-drug interactions (DDIs) were ordered. 
Materials and Methods 
We investigated 5 strategies which combined the features (i) prediction triggered 
at onset of DDI vs. continuous monitoring, with (ii) taking into account an 
increasing number of patient parameters. The considered patient parameters 
were identified using generalized additive models, and the thresholds of the 
prediction strategies were calculated by applying Youden’s J statistic to receiver 
operation characteristic curves. Half of the data served as calibration set, half as 
validation set. 
Results 
We identified 132 hyperkalemias induced by 8,413 potentially severe potassium-
increasing DDIs among 76,467 patients. The positive predictive value (PPV) of 
those strategies predicting hyperkalemia at onset of DDIs ranged from 1.79% 
(undifferentiated anticipation of hyperkalemia due to the DDI) to 3.02% 
(additionally considering the baseline serum potassium) and 3.10% (including 
further patient parameters). However, continuous monitoring significantly 
increased the PPV to 8.25% (considering the current serum potassium) and 
9.34% (additional patient parameters). 
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Conclusion 
Continuous monitoring of the risk for hyperkalemia based on the current 
potassium level shows a better predictive power than predictions triggered at 
onset of DDIs. This contrasts with efforts improving DDI alerts by taking into 
account more patient parameters at the time of ordering. 
  
Page 3 of 29
https://mc.manuscriptcentral.com/jamia
Journal of the American Medical Informatics Association
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
4 
BACKGROUND AND SIGNIFICANCE 
Drug-drug interactions (DDIs) are an important cause of adverse drug events 
(ADEs) leading to increased morbidity and mortality.(1, 2) Although most DDIs 
are preventable, up to 28% of inpatients suffer from DDI-induced ADEs.(3) 
It has been suggested that clinical decision support (CDS) can intercept the 
ordering of medications triggering DDIs. (4, 5) While some authors have pointed 
out that DDI alerts may prevent ADEs,(6) so far no study showed that CDS 
significantly reduces the frequency of ADEs. In particular, alert override rates of 
up to 98% hamper the potential of CDS interventions.(7, 8) Reasons for non-
adherence are the low specificity and clinical insignificance of electronic 
alerts.(9) Therefore, electronic warnings displayed for patients with a low risk for 
developing respective ADEs should be suppressed.(8-11) 
Approaches to increase the alert specificity are focusing on high-priority DDIs or 
tiering DDIs by severity,(12-14) considering patient factors and co-medication in 
order to suppress insignificant alerts,(15) and combinations of these 
approaches.(9, 16-18) On the one hand, patient factors are typically considered 
only at the time of ordering, on the other hand, conditions changing later on may 
critically influence the risk that an ADE occurs.(9, 15, 16) Therefore, sophisticated 
algorithms taking into account the change of dynamic patient parameters over 
time have been advocated.(17-20) A promising approach to improve medication 
safety may be to display warnings as soon as an ADE is imminent or likely to 
occur, instead of undifferentiated alerts at the time of ordering. However, to our 
knowledge, no comparison of (i) predictions of ADEs triggered at the time of 
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ordering with (ii) serial predictions based on a continuous monitoring has been 
published so far. 
We undertook this comparison study using retrospective data on potassium-
increasing DDIs. These DDIs occur in up to 10% of hospitalized patients (1, 3). 
Hyperkalemia is found in 1.9% of these DDIs (21) and can induce life-threatening 
cardiac arrhythmias.(22) To our knowledge, the number of hyperkalemias due to 
avoidable potassium-increasing DDIs has not been quantified so far, and 
therefore we also included the results of this prerequisite in our results section. 
 
OBJECTIVE 
To model and compare different strategies predicting hyperkalemia in 
hospitalized patients for whom medications triggering potassium-increasing DDIs 
were ordered. 
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MATERIALS AND METHODS 
Setting 
The University Hospital Zurich, Switzerland, is a tertiary care academic medical 
center with 850 beds and approximately 35,000 admissions per year. We 
included data of all inpatients from 1
st
 of December 2009 to 31
st
 of December 
2011. Patients undergoing dialysis and those hospitalized in intensive care units 
were excluded. 
The local research ethics committee approved the analyses, and patient consent 
was waived. 
Analyzed Patient Parameters 
We analyzed the following patient parameters potentially influencing the serum 
potassium (K
+
) level: age, gender, medications (severity level of potassium-
increasing DDI, duration of potassium-increasing DDI, numbers of concurrent 
potassium-increasing drugs, number of concurrent potassium-decreasing drugs), 
recent blood transfusion, comorbidities (kidney failure expressed by glomerular 
filtration rate, kidney transplant, diabetes mellitus, hypertension, heart failure, 
lung transplant), the unit (surgical versus non-surgical specialties), most recent 
serum K
+
 within 48 hours prior to the onset of the DDI (“baseline K
+
”), and finally 
the temporal change of the serum K
+
 level during the DDI.(21) 
DDIs and Potassium-Increasing Drugs 
DDIs were identified using the knowledge base galdat/hospINDEX (distributed by 
e-mediat AG, Berne, Switzerland; derived from ABDATA Pharma-Daten Service, 
Werbe- und Vertriebsgesellschaft Deutscher Apotheker, Eschborn, Germany), 
which tiers DDIs into six levels of severity.(23) Levels 1 to 3 categorize severe 
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DDIs (1: recommendation “contraindicated”, 2: “contraindicated as precaution”, 
3: “monitoring or adaptation required”) and were considered in the present 
study, whereas levels 4 to 6 were excluded (4: “monitoring or adaption in case of 
risk factors”, 5: “monitoring as a precaution”, 6: “no action required”). 
Potassium-increasing drugs were defined as drugs involved in severe potassium-
increasing DDIs, including angiotensin-converting enzyme inhibitors (ACE 
inhibitors), angiotensin antagonists (angiotensin-receptor blockers), direct renin 
inhibitors, immunosuppressive agents (calcineurin inhibitors), potassium-sparing 
diuretics (aldosterone-receptor antagonists and epithelial sodium channel 
blockers), K
+
 supplements and trimethoprim (ingredient of co-trimoxazole). 
Hyperkalemia 
Hyperkalemia was defined as serum K
+
 level of ≥5.5 mEq/l.(24) Each 
hyperkalemia was verified by chart review, and cases with documented 
measurement issues, e.g. incorrect blood sampling or incorrect handling, were 
excluded. In addition, corrective actions taken by the healthcare professionals 
were recorded and compared to the best therapeutic options on a case-by-case 
basis.(25) Only occurrences of hyperkalemia detected during potassium-
increasing DDIs were reviewed. The chart review was performed by an 
experienced internist (M.S.). 
Modeling of Prediction Strategies 
We modeled five different prediction strategies (labelled “P” as in “Prediction”, 
figure 1) comparing their strength to correctly predict the occurrence of 
hyperkalemia during potassium-increasing DDIs. Data from patients already 
presenting a hyperkalemia at onset of the DDI were excluded. 
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8 
The three “Pinitial“ prediction strategies were triggered only once, i.e. at onset of 
the potassium-increasing DDI. Thus, they predicted the risk of hyperkalemia for 
the entire DDI period (referred to as “long-term predictions”). These “Pinitial“ 
strategies took into account a stepwise increasing number of factors influencing 
the serum K
+
 level: 
(i) no parameter at all (Pinitial
none ) 
(ii) the baseline serum K
+
 level (Pinitial
K+ ) and  
(iii) all patient factors significantly influencing the K
+
 level (Pinitial
GAM ) 
according to prior work.(21) 
In contrast, both “Pduring” prediction strategies were triggered not only at onset 
of the DDI, but again for each serum K
+
 level measured during the DDI. These 
strategies predicted the risk of hyperkalemia for the next 48 hours (referred to as 
“short-term predictions”) and considered  
(iv) merely the current serum K
+
 level (Pduring
K+ ), versus  
(v) all patient parameters affecting the serum K
+
 progress (Pduring
GAM ). 
The patient data were split into a calibration set (used for building the strategies) 
and a validation set (used for validating the strategies) by applying a sample cube 
method (26) in order to generate robust models and to avoid overfitting. A 
balanced distribution was obtained by splitting the patients under consideration 
of a balanced allocation of patient factors influencing the serum K
+
 level. 
The calibration was performed depending on the prediction strategy: For 
strategy “Pinitial
K+ ”, the threshold for predicting a hyperkalemia was calculated by 
applying Youden’s J statistic to a receiver operation characteristic (ROC) curve 
built on the baseline serum K
+
 level.(27) The strategy “Pduring
K+ ” additionally took 
Page 8 of 29
https://mc.manuscriptcentral.com/jamia
Journal of the American Medical Informatics Association
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
9 
into account all K
+
 levels measured during the DDI period (followed by at least 48 
hours of unchanged potassium-increasing drug orders). “Pinitial
GAM ” was modeled 
using a generalized additive model (GAM): this algorithm selected those 
parameters at onset of the DDI that were most predictive for calculating the 
long-term risk of developing a hyperkalemia.(28) The threshold was again 
defined by applying Youden’s J statistic to the resulting ROC curve. For “Pduring
GAM ”, 
the GAM took into account all patient parameters that were predictive for the 
short-term risk of developing a hyperkalemia. 
The ROC areas under the curve (AUCs) were compared with DeLong’s Test,(29) 
and the p value was adjusted with Hommel’s method.(30) 
For the validation of “Pinitial” predictions, a subsequent hyperkalemia was defined 
as a hyperkalemia occurring anytime during the DDI. In contrast, for the 
validation of “Pduring” predictions, an imminent hyperkalemia was defined as a 
hyperkalemia occurring between the current time and the next 48 hours. In 
order to give equal weight to each patient and the respective parameters, the 
validation of the prediction strategies considered only the first event 
(subsequent risk of or occurrence of hyperkalemia) per patient. 
Hypothetical Monitoring Reminders 
We added two hypothetical monitoring reminders (labelled “M” as in 
“Monitoring”, figure 1) to foster periodic serum K
+
 measurements, a prerequisite 
for the prediction strategies studied: Minitial, ensuring that a recent serum K
+
 level 
is known at onset of the DDI, and Mduring, encouraging regular serum K
+
 
monitoring. 
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10 
The number of hypothetical monitoring reminders required was calculated using 
the same validation set as the one used to validate the prediction strategies. The 
analysis was carried out with two different intervals: The short monitoring 
interval of 48 hours was adopted from our previous study which showed that 
monitoring intervals exceeding 48 hours during potassium-increasing DDIs were 
associated with a higher risk for hyperkalemia.(21) However, the other defined 
interval was 72 hours in order to investigate a potential reduction of the number 
of hypothetical monitoring reminders. 
Statistical analyses 
Data analyses, model constructions and statistical tests were performed using 
the R language and environment for statistical computing, version 3.2.1 (R 
Foundation for Statistical Computing, Vienna, Austria). The R package “sampling” 
was used to split the data into calibration and validation set, “pROC” to plot ROC 
curves, and “mboost” to model and validate GAMs. p values of ≤0.05 were 
considered to be statistically significant. 
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RESULTS 
We analyzed the data of 76,467 inpatients (mean age 49.6 years, 50.3% females) 
for whom a total of 1,543,578 drugs were prescribed, including 77,799 
potassium-increasing drugs (5.0%). They resulted in 8,413 potentially severe 
potassium-increasing DDIs concerning 5,637 inpatients (mean age 65.8 years, 
31.3% females).(21) Of those patients, 90 developed a total of 132 hyperkalemic 
events during the DDIs. 
The charts reviews to record the measures taken after these hyperkalemic 
events revealed that more than half of the DDIs remained unchanged although a 
number of corrective actions should have been taken (table 1). The finding that 
only half of the orders were modified after a hyperkalemic event despite the fact 
that this would have been appropriate for all cases documents the need to alert 
the physician in charge when a hyperkalemia has occurred. 
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Table 1: 
Observed versus preferred actions following the 132 hyperkalemic K
+
 levels 
measured during potassium-increasing drug-drug interactions. 
Actions Observed1 Preferred2 
Modifying the drug order of ≥1 interacting drug 47 (43.2%) 132 (100.0%) 
 Discontinuing ≥1 interacting drug 26 (19.7%) 36 (27.3%) 
 Switching ≥1 interacting to another drug 0 (0.0%) 89 (67.4%) 
 Pausing ≥1 interacting drug 31 (23.5%) 7 (5.3%) 
Starting potassium-decreasing therapy 62 (47.0%) 112 (84.8%) 
No measures taken 39 (29.5%) 0 (0.0%) 
 
1
 Actions observed within 24h of hyperkalemic K
+
 level measurements. The actions 
consist of modifications of actual potassium-increasing drug orders and / or of beginning 
a potassium-decreasing therapy. 
2
 Action recommended by expert based on chart review. 
K
+
, serum potassium level.  
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The investigated five prediction strategies are presented in figure 1. Three of 
them, the “Pinitial“ predictions, were triggered at onset of each potassium-
increasing DDI only. The risk of hyperkalemia was calculated for the entire period 
of the DDI (long-term predictions), taking into account an increasing number of 
parameters influencing the serum K
+
 level. The two “Pduring” predictions were 
additionally triggered for each serum K
+
 level measured during the DDI, and 
calculated the risk of hyperkalemia for the next 48 hours (short-term 
predictions). 
The predictive power of the strategies divides them into two categories (table 2): 
The short-term predictions of hyperkalemia (Pduring) featured a significantly 
higher positive predictive value (PPV) than the long-term predictions (Pinitial). In 
contrast, within the two categories, there was only a trend of the predictive 
strength between the strategies: The long-term PPV insignificantly increased 
from “Pinitial
none ”, through “Pinitial
K+ ” to “Pinitial
GAM ”. Also, a trend of the PPV was observed 
between the short-term predictions from “Pduring
K+ ” to "Pduring
GAM ”. The increase of 
the predictive power is reflected by the ROC AUC: Both strategies using short-
term predictions performed significantly better compared to the long-term 
prediction “Pinitial
K+ ”. 
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Table 2: 
Evaluation of strategies predicting hyperkalemia in potassium-increasing drug-drug interactions. 
Label Model calibration  Model validation
1  
 Parameters used ROC 
AUC 
ROC AUC 
comparison (p)
2 
 Alerts
3 TP FP FN TN Sens. Spec. PPV 
95% CI 
NPV 
Pinitial
none  None - -  1'619 29 1'590 0 0 100.0% 0.0% 1.79% 
1.20-2.56% 
- 
Pinitial
K+  Last K
+
 before onset of DDI 
≥ 4.3 mEq/l 
0.603 -  398 12 386 17 1'192 41.4% 75.5% 3.02% 
1.57-5.21% 
98.8% 
Pinitial
GAM  7 patient parameters: 
last K
+
 before onset of DDI, 
GFR, number of potassium-
increasing drugs, number 
of potassium-decreasing 
0.786 vs. Pinitial
K+  (0.067)  387 12 375 16 1'105 42.9% 74.7% 3.10% 
1.61-5.35% 
98.6% 
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15 
drugs, blood transfusion, 
age, clinic 
Pduring
K+  Current K
+
 ≥ 4.5 mEq/l 0.839 vs. Pinitial
K+  (0.007*) 
vs. Pinitial
GAM  (0.770) 
 303 25 278 13 1'133 65.8% 80.3% 8.25% 
5.41-
11.94% 
98.9% 
Pduring
GAM  5 patient parameters: 
current K
+
, severity level of 
DDI, number of potassium-
increasing drugs, number 
of potassium-decreasing 
drugs, duration since onset 
of DDI 
0.841 vs. Pinitial
K+  (0.006*) 
vs. Pinitial
GAM  (0.735) 
vs. Pduring
K+  (0.976) 
 289 27 262  7 756 79.4% 74.3% 9.34% 
6.25-
13.30% 
99.1% 
 
1
 In order to give equal weight to each patient and to his or her specific set of parameters, the validation assessed merely the first event per patient (either alert 
or hyperkalemic event). 
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2 
calculated on the basis of DeLong's Test for comparison; subsequently corrected with Hommel's method for adjustment of p values for multiple comparisons. 
3
 numbers of hypothetical alerts calculated by simulations using data from the validation set. 
ROC AUC, area under the receiver operating characteristic curve. 
TP, true positive. FP, false positive. FN, false negative. TN, true negative. Sens., sensitivity. Spec., specificity. PPV, positive predictive value. NPV, negative 
predictive value, CI, confidence interval. 
GFR, glomerular filtration rate, *, statistically significant. 
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17 
The ROC of “Pduring
K+ ” illustrates the tradeoff between specificity and sensitivity in 
function of the threshold value (figure 2). The superimposed ROC curves of all 
five strategies (figure 3) show that the short-term predictions “Pduring
K+ ” and 
“Pduring
GAM ” have similar curves and perform better than the long-term predictions 
“Pinitial”. 
We added hypothetical K
+
 monitoring reminders to the prediction strategies to 
ensure that K
+
 levels would be available to the prediction models (figure 1).(31) 
The simulation of the required monitoring reminders showed that medications 
triggering potassium-increasing DDIs were ordered without knowledge of the 
current serum K
+
 level in 12% to 15% of the patients (time intervals of 72 and 48 
hours, respectively; table 3). Considering the K
+ 
monitoring during the entire 
duration of the DDIs, the serum K
+
 was not measured within monitoring intervals 
of 72 hours in 22% and within intervals of 48 hours in 36% of the patients. 
Table 4 illustrates the potential alert burden by summarizing the number of 
hypothetical monitoring reminders and the number of hypothetical alerts 
warning against the risk of hyperkalemia according to the five strategies 
analyzed. 
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Table 3: 
Numbers of hypothetical reminders for different serum K
+
 monitoring strategies 
during potassium-increasing DDIs. 
Δt Reminders at onset of DDI1 Reminders at onset of and during DDI1 
 Label Trigger # (%
2
) Label Trigger3 # (%2) 
48h Minitial
48h  if no K
+
 level is 
available within 48h 
prior to the onset of 
the DDI 
154 
(15%) 
Mduring
48h if no K
+
 level is 
available within 
48h prior to the 
current check 
375  
(36%) 
72h Minitial
72h  if no K
+
 level is 
available within 72h 
prior to the onset of 
the DDI 
123 
(12%) 
Mduring
72h if no K
+
 level is 
available within 
72h prior to the 
current check 
231  
(22%) 
 
1
 In order to allow for comparison with table 2, merely the first event per patient was 
assessed. 
2
 Reminders in percentage of the total number of patients included within the validation 
set. 
3
 This condition is continuously tested during the entire period of each potassium-
increasing DDI. 
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Table 4: 
Number of hypothetical alerts warning against the risk for hyperkalemia and of 
hypothetical potassium monitoring reminders. 
Triggering event Alerts Reminders Total
1 
strategy # strategy # 
Start of DDI 
Pinitial
none  1,619 - 0 1,619 
Pinitial
K+  398 Minitial
72h  123 521 
Pinitial
GAM  387 Minitial
72h  123 510 
Start of DDI and each serum 
K
+
 measurement during DDI 
Pduring
K+  303 Mduring
72h  231 534 
Pduring
GAM  289 Mduring
72h  231 520 
 
1
 sum of number of alerts plus number of reminders. 
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DISCUSSION 
The goal of the study was to evaluate and compare five distinct strategies in 
terms of their ability to predict the risk of hyperkalemia during potassium-
increasing DDIs in order to prevent hyperkalemia by means of alerts. Our analysis 
shows that short-term predictions, similar to a continuous monitoring of DDIs, 
perform significantly better than long-term predictions exclusively triggered at 
onset of potassium-increasing DDIs. 
Besides providing up to three times higher PPVs, the switch from long-term to 
short-term predictions also improved the ROC AUC of the respective strategies, 
increased the sensitivity, but still decreased the potential alert burden. Of note, 
only short-term predictions achieved sensitivities of nearly 70%, a sensitivity 
considered to be adequate.(32) In contrast, taking into account further patient 
parameters affecting the development of hyperkalemia showed only a modest 
gain. Short-term predictions performed better with fewer parameters and thus 
with lower costs than long-term predictions. 
The GAM algorithm selected different patient parameters for the long- vs. short-
term prediction strategies: “Pinitial
GAM ” used the last serum K
+
 level measured before 
onset of the DDI and considered the number of drugs ordered affecting the 
serum K
+
 level, the kidney function, blood transfusions, age, and the unit. In 
contrast, “Pduring
GAM ” considered the severity level of the DDI, the previous duration 
of the DDI, and the number of drugs ordered affecting the serum K
+
 level and 
monitored the current serum K
+
 level. This is in line, however, with our 
observation (21) that the severity level is not helpful for long-term predictions of 
developing hyperkalemia. Noteworthy, the ordering of level 1 DDIs often relates 
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to the correction of hypokalemia, and this intentional treatment appears to be 
less likely to induce a hyperkalemia, possibly due to a closer serum K
+
 monitoring 
by the healthcare professionals in charge. 
Serial predictions of the risk for hyperkalemia during potassium increasing DDIs 
require regularly updated laboratory values. Therefore, there is a need to 
stimulate the K
+
 monitoring by the providers. Such monitoring reminders may 
increase the alert burden, potentially undermining the aim to reduce the number 
of displayed notifications. However, an innovative approach mitigating this issue 
would be the automated generation of K
+
 measurement orders – and no more 
monitoring reminders would then be necessary. 
If our described strategies would be implemented in an electronic health record 
as automated notifications, both (i) alerts warning against the risk of 
hyperkalemia, and (ii) monitoring reminders, could unobtrusively make 
recommendations to the providers at the time of order entry. Also, (i) alerts and 
(ii) monitoring reminders triggered during the DDI could be displayed in a non-
interruptive manner e.g. in the overview of current medication orders or 
laboratory results. Overdue serum K
+
 measurements could be prefilled 
automatically in laboratory order forms. The alerts warning against the risk of 
hyperkalemia described above should be complemented by actual hyperkalemia 
alerts (serum potassium level ≥5.5mEq/l). These supplementary alerts would 
draw the physician’s attention to the fact that the actual drug therapy may 
aggravate the already present hyperkalemia. 
Our study has several limitations. First, the data were obtained from a single site, 
which may limit the generalizability of the findings. In this context, the high 
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proportion of multimorbid patients and the frequent monitoring of laboratory 
results at our institution may have influenced the model thresholds, which 
should be validated on site before use in other institutions. Nevertheless, the 
described predictions can easily be implemented at other institutions, since the 
proposed strategies have been disclosed in detail. Second, only a single expert 
reviewed the patient charts to retrospectively assess treatment options following 
hyperkalemic events. Third, we assumed that the consequences of false positive 
and false negative alerts are comparable. We therefore calculated the alert 
threshold using the optimality criterion of Youden’s J statistic, giving equal 
weight to both specificity and sensitivity. Anyway, CDS interventions 
incorporating such predictions could take into account the stakeholders’ 
preference for specificity or sensitivity. Fourth, a PPV of less than 10% may 
appear insufficient, but this has to be interrelated with the low frequency of 
hyperkalemia during potassium-increasing DDIs (1.9%).(21, 33) 
Various approaches to improve the specificity of DDI alerts have been proposed, 
including focusing on high-priority DDIs,(12) tiering DDIs by severity,(13, 14) 
taking into account patient factors and co-medication,(15) and also considering 
the change of conditions over time (19), or a combination of these strategies.(9, 
16-18) However, the effects of these approaches have rarely been quantified: 
Paterno et al. demonstrated that tiering DDI alerts by severity increased the 
compliance by 19%.(13) Helmons et al. reduced the number of alerts by 55% by 
focusing on high-priority DDIs and considering critical patient parameters 3 times 
a day.(18) 
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To our knowledge, this is the first study comparing prediction strategies 
triggered exclusively at onset of potassium-increasing DDIs (long-term 
predictions) with serial prediction recalculations throughout the duration of the 
DDIs (short-term predictions). Our observation that the predictive power of 
alerts can be improved by focusing on short-term predictions may positively 
influence the crucial efforts to reduce the alert burden which in turn would 
minimize the risk for alert fatigue. Furthermore, this approach may be of 
importance for various other categories of prescription warnings, provided that 
the risk of potential ADEs may be monitored. 
Finally, predictions recalculated throughout the duration of DDIs can be 
combined with human factors principles.(34-39) For instance, the models 
presented could generate alerts with graduated priorities as a function of the 
alert threshold, such as medium risk notifications vs. warnings against a high risk 
of an imminent hyperkalemia. Finally, since alerting at the appropriate time is a 
central aspect of human factors principles, short-term predictions constitute a 
novel and important approach to address human factors. 
 
CONCLUSION 
In conclusion, our findings show that a continuous monitoring of the risk for 
hyperkalemia based on the current potassium level shows a better predictive 
power than predictions triggered at onset of DDIs. This contrasts with efforts of 
improving DDI alerts by taking into account more detailed patient data at the 
time of ordering, whereas algorithms continuously monitoring only the prime 
patient parameter perform likewise well. 
Page 23 of 29
https://mc.manuscriptcentral.com/jamia
Journal of the American Medical Informatics Association
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
24 
Figure Captions 
Figure 1: Design of alert and reminder strategies 
Figure 2: Receiver operating characteristic curve of prediction strategy Pduring
K+  
predicting hyperkalemia for the next 48 hours based on the current serum 
potassium level 
Figure 3: Comparison of the receiver operating characteristic curves of all 
evaluated prediction strategies 
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Figure 2: Receiver operating characteristic curve of prediction strategy PK+during predicting hyperkalemia for 
the next 48 hours based on the current serum potassium level  
129x129mm (300 x 300 DPI)  
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Figure 3: Comparison of the receiver operating characteristic curves of all evaluated prediction strategies  
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